Thank you for subscribing.

Please check your email to confirm.

Unsubscribe success..

You already subscribed and confirmed.

Please check your email.

You already subscribed.

Please check your email to confirm.

Chinese Biopharma and Health Tech to Show Up at JPMorgan's Event on Jan 15
Chinese Biopharma and Health Tech to Show Up at JPMorgan's Event on Jan 15
The annual J.P. Morgan Healthcare Conference is the largest healthcare investment symposium in the industry. Image: Credit to Pixabay.

Tens of conspicuous Chinese healthcare companies, mainly from Greater China's biotech and health tech scene, will be trying luring the capitalists with their 2020 strategy at JPMorgan's phenomenal healthcare conference in San Francisco's Union Square. EqualOcean has compiled the list of companies whose executives will be giving keynote speeches on 15 January at Westin St. Francis Hotel.

While some of them are widely known in healthcare-focused investment circles, such as immuno-oncology developer Beigene and Ping An Holding's healthcare arm,  some have yet to be explored by most of the attendees that will be attending the event. 

Temasek-backed Transcenta, for instance, which carried out its Series B funding round, worth over USD 100 million on January 8 – the company is the out-licenser to Eli Lily of an antagonist for osteoporosis that has been developed (now in Phase II) for the Greater China Region.

LinkDoc, a state-backed Chinese medical data provider who constantly fails in transparency, is yet another eye-catching firm that will be scrutinized by the attendees. The company provides IT and big-data services to accelerate the drug-development and application processes for pharmaceuticals. The firm will present at the 'Emerging Markets Forum' of the event.

Immuno-oncology biotech Adagene, will be representing recently-proliferated Chinese immunotherapy startups. This Sequoia-backed firm also announced that it has secured over USD 70 million last week. I-Mab Biopharma, a Shanghai-based immuno-oncology firm that will be publicly traded on January 16 on NASDAQ, will be alluded to with this relatively smaller company.

There will be exponential growth-seeking small and young firms as well: Qiming-backed Ark Biosciences and oncology biotech Dizal Pharma executives will be speaking at the Westin St. Francis Hotel on the same day.

Around 38 Chinese firms – an increase of 22.6 percent over last year – have made presentations and attended one-on-one meetings at the three-day event in 2020, SCMP found. EqualOcean will be reporting on the event, particularly on the Chinese private health tech firms that have lately been seeking growth from overseas investors and markets. 

Reach the Author!

Ask the author questions about the copied text

MOST READ

THE LATEST

Meituan Should Buy DiDi, Investors Say
Could this be the best offer ever?

Meituan Should Buy DiDi, Investors Say

Any Question

EqualOcean is an international information service provider and investment research firm that aims to become a global platform for industrial innovation.

We strive to make technology inclusive, accessible and transparent.

Join over 70,000 of your peers